Aggressive Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Aggressive Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma [Phase 2]
The Phase 2 study of pixantrone in CD20+ relapsed/refractory aggressive non-Hodgkin lymphoma has completed.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma [Phase 1]
Phase 1 trial evaluating polatuzumab vedotin with chemotherapy, with or without glofitamab, for untreated aggressive large B-cell lymphoma. …
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial assessing pembrolizumab with external beam radiation therapy in relapsed or refractory non-Hodgkin lymphoma; the study (NCT032…
-
CLINICAL_TRIALS trial_result · 2025-12-31Clinical Trial Update: CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). [Phase 2]
A Phase 2 clinical trial is evaluating a combination of CAR-T cell therapy with mosunetuzumab and polatuzumab for refractory/relapsed aggres…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency [NA]
A Mayo Clinic-sponsored clinical trial evaluates cholecalciferol (vitamin D3) for improving survival in patients with newly diagnosed cancer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-12-18Clinical Trial Update: A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies [Phase 1]
A Phase 1 study of CNTY-101 in CD19-positive B-cell malignancies has been terminated.
-
CLINICAL_TRIALS withdrawal · 2025-09-17Clinical Trial Update: Testing the Safety of CB-5339 in Patients With Cancer [Phase 1]
The Phase 1 clinical trial of CB-5339 in cancer patients has been withdrawn, with no study results reported.
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy [Phase 2]
Phase 2 clinical trial update assessing high-dose chemotherapy for aggressive non-Hodgkin lymphoma and related lymphomas; study is completed…
-
CLINICAL_TRIALS trial_result · 2022-08-04Clinical Trial Update: Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study [Phase 1, Phase 2]
Phase 1/2 study evaluating a multi-agent regimen (pixantrone, etoposide, bendamustine +/- rituximab) in relapsed aggressive non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2022-04-05Clinical Trial Update: Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL [Phase 1, Phase 2]
Phase 1/2a dose-escalation study in CLL/SLL and various NHL subtypes completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 trial evaluating metronomic chemotherapy in elderly, non-fit patients with aggressive B-cell lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma [Phase 1]
This Phase I/Ib trial assesses safety and early efficacy signals for nivolumab plus veliparib in patients with advanced solid tumors and agg…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
CLINICAL_TRIALS research · 2016-05-13Clinical Trial Update: Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma [Phase 3]
Phase 3 trial update evaluating rituximab maintenance therapy for CD20-positive aggressive lymphoma and mantle cell lymphoma; no results are…
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). [Phase 2]
Phase 2 trial evaluating BeEAM conditioning (bendamustine, cytarabine, etoposide, melphalan) for autologous stem cell transplant in patients…
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas [Phase 2]
This completed Phase 2 trial evaluated the combination of Zevalin with BEAM high-dose chemotherapy followed by autologous stem cell transpla…
-
EMA approval · 2012-02-17European Medicines Agency recommends conditional approval of Pixuvri (pixantrone) for relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma
EMA recommends conditional approval of Pixuvri (pixantrone) for relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma.